Form 4: Aura Biosciences VP of Finance Sells Shares to Cover Tax Obligations

Aura Biosciences' Vice President of Finance, Amy Elazzouzi, sold 1,001 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Amy Elazzouzi, Vice President of Finance at Aura Biosciences, sold 1,001 shares of common stock on January 21, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $7.6715, with individual transactions ranging from $7.67 to $7.86 per share.
• Following the transaction, Ms. Elazzouzi directly owns 38,442 shares of Aura Biosciences common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no significant positive or negative implications for the company's outlook.

Industry Context

This is a routine transaction for company executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across publicly traded companies.
• The price range of $7.67 to $7.86 is within the typical range for such transactions, reflecting the market price of the stock at the time of the sale.
• Similar transactions can be observed in filings from other biotech companies such as Regeneron, Gilead, and Biogen.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Aura Biosciences, insider trading, stock sale, Form 4, Amy Elazzouzi, tax obligations, restricted stock units, share sale